W Early physical and occupational therapy in mechanically ventilated, critically ill patients: a randomised controlled trial

William D Schweickert, Mark C Pohlman, Anne S Pohlman, Celerina Nigos, Amy J Pawlik, Cheryl L Esbrook, Linda Spears, Megan Miller, Mietka Franczyk, Deanna Deprizio, Gregory A Schmidt, Amy Bowman, Rhonda Barr, Kathryn E McCallister, Jesse B Hall, John P Kress

Summary

Lancet 2009; 373: 1874-82

Published Online May 14, 2009 DOI:10.1016/S0140-6736(09)60658-9

See Comment page 1824

Department of Medicine. Division of Pulmonary, Allergy and Critical Care Medicine, University of Pennsylvania. Philadelphia, PA, USA (W D Schweickert MD); Department of Medicine, Section of Pulmonary and Critical Care (M C Pohlman MD. A S Pohlman MSN, C Nigos RN, K E McCallister BS, Prof I B Hall MD, J P Kress MD), and Therapy Services Department (A J Pawlik PT, C L Esbrook OTR/L, L Spears PT, M Miller OTR/L, M Franczyk PT, D Deprizio OTR/L), University of Chicago, Chicago, IL, USA; and Department of Internal Medicine, Division of Pulmonary Diseases, Critical Care, and Occupational Medicine (Prof G A Schmidt MD, A Bowman BSN), and Department of Rehabilitation Therapies (R Barr PT). University of Iowa, Iowa City, IA, USA

Correspondence to Dr John P Kress, Department of Medicine, Section of Pulmonary and Critical Care, University of Chicago, 5841 South Maryland, MC 6026, Chicago, IL 60637, USA

jkress@medicine.bsd.uchicago. edu

Background Long-term complications of critical illness include intensive care unit (ICU)-acquired weakness and neuropsychiatric disease. Immobilisation secondary to sedation might potentiate these problems. We assessed the efficacy of combining daily interruption of sedation with physical and occupational therapy on functional outcomes in patients receiving mechanical ventilation in intensive care.

Methods Sedated adults (≥18 years of age) in the ICU who had been on mechanical ventilation for less than 72 h, were expected to continue for at least 24 h, and who met criteria for baseline functional independence were eligible for enrolment in this randomised controlled trial at two university hospitals. We randomly assigned 104 patients by computer-generated, permuted block randomisation to early exercise and mobilisation (physical and occupational therapy) during periods of daily interruption of sedation (intervention; n=49) or to daily interruption of sedation with therapy as ordered by the primary care team (control; n=55). The primary endpoint—the number of patients returning to independent functional status at hospital discharge-was defined as the ability to perform six activities of daily living and the ability to walk independently. Therapists who undertook patient assessments were blinded to treatment assignment. Secondary endpoints included duration of delirium and ventilator-free days during the first 28 days of hospital stay. Analysis was by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00322010.

Findings All 104 patients were included in the analysis. Return to independent functional status at hospital discharge occurred in 29 (59%) patients in the intervention group compared with 19 (35%) patients in the control group (p=0.02; odds ratio 2.7 [95% CI 1.2-6.1]). Patients in the intervention group had shorter duration of delirium (median 2.0 days, IQR 0.0-6.0 vs 4.0 days, 2.0-8.0; p=0.02), and more ventilator-free days (23.5 days, 7.4-25.6 vs 21.1 days, 0.0-23.8; p=0.05) during the 28-day follow-up period than did controls. There was one serious adverse event in 498 therapy sessions (desaturation less than 80%). Discontinuation of therapy as a result of patient instability occurred in 19 (4%) of all sessions, most commonly for perceived patient-ventilator asynchrony.

Interpretation A strategy for whole-body rehabilitation-consisting of interruption of sedation and physical and occupational therapy in the earliest days of critical illness-was safe and well tolerated, and resulted in better functional outcomes at hospital discharge, a shorter duration of delirium, and more ventilator-free days compared with standard care.

Funding None.

Introduction

Advances in the management of mechanically ventilated patients have improved outcomes and survival rates for this patient population.1-3 As patients survive acute illness, long-term complications are more apparent. Weakness is a frequent complication and is associated with major disability and protracted rehabilitation.4-6 In addition to physical debility, neuropsychiatric dysfunction is often profound. Delirium during intensive care unit (ICU) stay (ICU-associated delirium) is common in patients undergoing mechanical ventilation, and is associated with increased mortality,7 longer length of stay in intensive care and in hospital,8 and increased duration of ventilation.7

Clinicians working in the ICU often focus on treating circulatory, respiratory, and renal function to ensure patient survival. Accordingly, most patients on mechanical ventilation receive sedative and analgesic drugs

to reduce distress and oxygen consumption;9 however, this approach can result in long periods of unconsciousness and immobility.10 Protocols geared to keeping sedation to a minimum, such as daily interruption of sedation,11 and mobilisation of mechanically ventilated patients via physical therapy12,13 in the earliest days of critical care, can result in improved patient outcomes. Specifically, observational studies of patients on mechanical ventilation for at least 4 days who were subsequently transferred to a dedicated respiratory ICU (post-acute care) have shown that physical therapy is feasible, safe, and promotes more rapid return to ambulation.^{12,13} More recently, in a prospective, nonrandomised cohort study, Morris and colleagues¹⁴ showed that an early mobilisation team increased physical therapy services for medical ICU patients with respiratory failure; this intervention also shortened length of stay in the ICU and in hospital.

Additionally, the identification of ICU-associated delirium and its association with poor outcomes has highlighted the need for interventions that might alter its course.¹⁵ Although several possible factors might result in ICU-associated delirium, so far only sedation with dexmedetomidine as a replacement for a benzodiazepine has been shown to reduce the duration of ICU-associated delirium.¹⁶

The implementation of daily interruption of sedation combined with physical and occupational therapy in the earliest days of critical illness might prevent sedativerelated immobility. We postulated that this intervention, tested in a randomised controlled trial, would affect both functional outcomes and neuropsychiatric outcomes, such as ICU-associated delirium.

Methods

Patients

We recruited study participants at two medical centres: University of Chicago Medical Center (Chicago, IL, USA) and University of Iowa Hospitals (Iowa City, IA, USA). The institutional review boards at both centres approved the study, and written informed consent was obtained from participants or their authorised representatives.

Patients in the medical ICU were screened daily to identify adults (>18 years of age) who had been on mechanical ventilation for less than 72 h, were expected to continue for at least 24 h, and who met criteria for baseline functional independence (defined a priori as a Barthel Index score >70 obtained from a proxy describing patient function 2 weeks before admission).^{17,18} Patients were excluded for the following reasons: rapidly developing neuromuscular disease, cardiopulmonary arrest, irreversible disorders with 6-month mortality estimated at more than 50%, raised intracranial pressure, absent limbs, or enrolment in another trial.

Procedures

Patients were randomly assigned in a 1:1 ratio to exercise and mobilisation (physical and occupational therapy) beginning on the day of enrolment (intervention) or to standard care with physical and occupational therapy delivered as ordered by the primary care team (control). Neither site routinely provides physical therapy for patients who are on mechanical ventilation for less than 2 weeks, nor has dedicated physiotherapists for such practice. At both sites, a computer-generated, permuted block randomisation scheme was used to allocate patients to study group. Each assignment was designated in a consecutively numbered, sealed, opaque envelope by an investigator with no further involvement in the trial.

Every morning, unresponsive patients in the intervention group underwent passive range of motion exercises for all limbs (ten repetitions in all cardinal directions). Sedatives were interrupted as previously described.¹ Therapy was delivered by a physical and occupational therapist and coordinated with daily interruption of sedation. Once patient interaction was achieved, sessions began with active assisted (with manual assistance) and active (independent) range of motion exercises in the supine position. If these exercises were tolerated, treatment was advanced to bed mobility activities, including transferring to upright sitting. Sitting balance activities were followed by participation in activities of daily living (ADLs) and exercises that encouraged increased independence with functional tasks. The session progressed to transfer training (ie, repetition of sit-to-stand transfers from bed to chair or bed to commode), and finally pre-gait exercises and walking. Progression of activities was dependent on patient tolerance and stability. Therapy intervention continued on a daily basis throughout the patient's hospital stay until he or she returned to a previous level of function or was discharged.

The following criteria indicated unstable patient conditions that prevented the initiation or continuation of physical and occupational therapy: mean arterial blood pressure less than 65 mm Hg or more than 110 mm Hg, or systolic blood pressure more than 200 mm Hg; heart




Figure 1: Trial profile

ICU=intensive care unit. ITT=intention-to-treat. *Defined as a Barthel Index score describing health 2 weeks before admission of less than 70.

	Intervention (n=49)	Control (n=55)
Age (years)	57.7 (36.3–69.1)	54·4 (46·5–66·4)
Female	29 (59%)	23 (42%)
Black race	30 (61%)	31 (56%)
Barthel Index score	100 (85–100)	100 (90–100)
Body-mass index (kg/m²)	27.4 (25.1–32.4)	28.0 (23.5-34.1)
APACHE II score	20.0 (15.8–24.0)	19.0 (13.3–23.0)
Sepsis	42 (86%)	45 (82%)
Diabetes	18 (37%)	18 (33%)
Primary diagnosis on admiss	ion to intensive care	
Acute lung injury	27 (55%)	31 (56%)
COPD exacerbation	4 (8%)	6 (11%)
Acute exacerbation of asthma	5 (10%)	4 (7%)
Sepsis	7 (14%)	9 (16%)
Haemorrhage	1(2%)	2 (4%)
Malignancy	2 (4%)	1(2%)
Other	3 (6%)	2 (4%)

Data are number of patients (%) or median (IQR). APACHE II=Acute Physiology and Chronic Health Evaluation II. COPD=chronic obstructive pulmonary disease. Barthel Index scale 0–100, APACHE II scale 0–71.

Table 1: Baseline characteristics of the study population

rate less than 40 beats per min or more than 130 beats per min; respiratory rate less than 5 breaths per min or more than 40 breaths per min; and pulse oximetry less than 88%. Additionally, the following findings were contraindications for initiation of therapy: raised intracranial pressure; active gastrointestinal blood loss; active myocardial ischaemia; continuing procedures including intermittent haemodialysis (but not including continuous ultrafiltration or haemodialysis); patient agitation that needed increased sedative administration in the past 30 min; and unsecure airway. Further criteria that prevented continuation of therapy were marked ventilator asynchrony; patient distress (evidenced by non-verbal cues, gestures); the patient being physically combative; new arrhythmia; concern for myocardial ischaemia; and concern for airway device integrity.

Patients in both intervention and control groups were managed by goal-directed sedation guided by the Richmond Agitation Sedation Scale (RASS)^{19,20} and underwent daily interruption of sedatives or narcotics, or both. Contraindications to daily interruption of sedation were: persisting neuromuscular blockade; sedative infusion for active seizures or alcohol withdrawal; escalating sedative doses because of persisting agitation; evidence of active myocardial ischaemia in the previous 24 h; and evidence of raised intracranial pressure. Study personnel undertook daily independent neurological assessments of patients by use of the RASS for level of arousal and the Confusion Assessment Method for the ICU for delirium and coma.^{21,22}

Weaning patients from mechanical ventilation was done via a protocol,³ with the decision to extubate made

by the primary care team. All patients were started on enteral feeding and those who showed three glucose concentrations of more than 8.3 mmol/L were treated with insulin infusions.²³

The primary endpoint was defined a priori as the number of patients returning to independent functional status at hospital discharge. Independent functional status was defined as the ability to perform six ADLs (bathing, dressing, eating, grooming, transferring from bed to chair, using the toilet)^{24,25} and walking independently. Historically, functional assessments of survivors of critical illness include outcomes of ADLs and walk distance.^{412,13,26,27} This composite endpoint was selected to reflect these milestones and the targeted goals of the intervention. The rating scale of the Functional Independence Measure was used to quantify functional status. ADL scores that were rated \geq 5 were deemed as performed independently by the patient (ie, no need for physical assistance).²⁸

Secondary endpoints were: (1) number of hospital days with delirium; (2) number of days alive and breathing without assistance (ventilator-free days) during the first 28 days of hospital stay; and (3) length of stay in the ICU and in hospital. Additionally, the following measurements were taken at hospital discharge: (1) Barthel Index score; (2) number of functionally independent ADLs; (3) distance walked without assistance; (4) number of patients diagnosed with ICU-acquired paresis;²⁹ and (5) hand-grip strength scoring at ICU and hospital discharge.

Patients were assessed by physical and occupational therapists who were unaware of randomisation assignment. Every 48 h, these therapists assessed patient strength and ability to perform ADLs and to walk, including a final assessment and Barthel Index scoring within 24 h of discharge. Strength in the upper and lower extremities was scored by use of the Medical Research Council (MRC) examination,^{30,31} followed by three measurements of dominant hand dynamometry (Jamar hand-grip dynamometer; Sammons Preston Rolyan, Bolingbrook, IL, USA). ICU-acquired paresis was diagnosed when an awake and attentive patient had a muscle strength sum score of less than 48 when all muscle groups were able to be assessed.²⁹

To maintain blinding, the group of assessment therapists was distinct from the therapists who undertook the intervention. Before each assessment, the patients and any visitors were instructed (via a structured introductory statement) not to discuss previous interventions. Furthermore, assessments occurred in the afternoon at a time distant from the morning therapy intervention.

Safety was monitored by research staff and bedside nurses continuously during the study. In accordance with the requirements of the institutional review boards, if research-related adverse events were to occur, the intervention should be stopped, followed by immediate medical treatment in the ICU. Furthermore, all serious adverse events were to be reported to the institutional review boards within 48 h.

Therapy sessions in which the patient met the criteria for instability or in which unplanned extubation or equipment removal occurred were tracked prospectively. Individual decisions by the primary care team or intervention team to discontinue a therapy session were categorised and reported. Serious adverse events, in accordance with recently published literature, included fall to knees, endotracheal tube removal, systolic blood pressure more than 200 mm Hg, systolic blood pressure less than 90 mm Hg, and desaturation to less than 80%.12 Finally, the time to taken to accomplish additional functional milestones (such as the first day getting out of bed, standing, marching in place, transferring to a chair, walking [even with assistance]) were recorded from nursing and physiotherapy notes to emphasise patient progression in the two groups.

Statistical analysis

On the basis of observations of functional outcomes in a cohort of critically ill patients with respiratory failure who were functional at admission to intensive care, we noted that 50% of patients achieved return of independent functional status at hospital discharge. We calculated that a total sample size of 100 patients would be needed to detect a 30% difference in the number of patients achieving return to independent functional status between the two groups with 80% power and a two-sided significance level of 0.05.

Data were analysed by an intention-to-treat approach. Patients who died during the study were assigned scores of 0 for ventilator-free days, strength testing (MRC examination and hand grip), ADL total, walk distance, and Barthel Index score. We used the χ^2 test or Fisher Exact test (as appropriate) to compare categorical variables between the two study groups, including the primary endpoint, and the Wilcoxon-Mann-Whitney two-sample rank-sum test or *t* tests to compare continuous variables.

To compare the effect of the treatment protocol on the time to return to independent functional status, we used time-to-event analysis. A cumulative event curve (censored endpoints) was estimated with the Kaplan-Meier procedure. The effect of the treatment protocol on the endpoint was compared between groups with the logrank test. Additional analysis was done with logistic and Cox regression models that adjusted for the main baseline factors that predict outcomes (age, APACHE II, presence of sepsis) and the presence of the intervention. We checked the assumption of proportionality of hazard functions in our Cox regression model. Hazard ratios (HRs), together with 95% CIs, were estimated with these models. To assess for an interaction between study centre and treatment with respect to the primary endpoint, we included an interaction term in a proportional odds logistic

Daily interruption of sedation Days of sedation with DIS (%)* 100% (100-100) 100% (100-100) 0-56 Duration of DIS per patient (h per day) 2.7 (0.8-6-5) 3.3 (1-0-8-9) 0.35 Time on mechanical ventilation with DIS (%)† 14% (5-33) 20% (5-44) 0.36 Sedation and analgesia duration Ventilation (days) 2.7 (1.5-5-5) 4.3 (2.5-6-8) 0.06 Time on sedation (%)‡ 69% (27) 68% (27) 0.84 0.06 Opiate duration (days) 2.3 (1.3-4-3) 3.3 (1.7-6-1) 0.14 Time on opiate (%)‡ 65% (42-89) 71% (32-86) 0.64 Coma (days) 0.0 (0.0-0.2) 1.0 (0.0-3.0) 0.12 ICU days with coma (%) 0% (0-15) 8% (0-27) 0.21 Dry details, sedative and analgesic agents Patients receiving propofol 48 (98%) 53 (96%) 1.0 Morphine equivalents (mg/h) 0.02 (0.0-0.3) 0.02 (0.0-0.2) 0.83 Patients receiving phatodiazepine 39 (80%) 44 (87%) 0.43		Intervention (n=49)	Control (n=55)	p value
Duration of DIS per patient (h per day) 2.7 (0.8-6-5) 3.3 (1.0-8-9) 0.35 Time on mechanical ventilation with DIS (%)† 14% (5-33) 20% (5-44) 0.36 Sedation and analgesia durationSedation duration (days) 2.7 (1.5-5-5) 4.3 (2.5-6.8) 0.06 Time on sedation (%)‡ 69% (27) 68% (27) 0.84 Opiate duration (days) 2.3 (1.3-4.3) 3.3 (1.7-6.1) 0.14 Time on opiate (%)‡ 65% (42-89) 71% (32-86) 0.64 Coma (days) 0.0 (0.0-0.2) 1.0 (0.0-3.0) 0.12 ICU days with coma (%) 0.0 (0.0-15) 8% (0.27) 0.21 Dragetails, sedative and analgesic agentsPatients receiving popofol 48 (98%) 53 (96%) 1.0 Propofol dose (mg/h) 99 (46-136) 96 (53-141) 0.98 Patients receiving opiate 48 (98%) 54 (98%) 1.0 Morphine equivalents (mg/h) 0.20 (0.0-0.3) 0.02 (0.0-0.2) 0.89 Patients receiving haloperidol 8 (16%) 91 (16%) 0.80 Haloperidol (mg per day) $0(0-0-00)$ $0(0-0-00)$ 1.0 Nutrition and glycaemic controlSustained anxiety or agitationSign for esamption of sedation following interversinSustained pain $5(4\%)$ $5(3\%)$ 0.74 Odo (Joucee, morning concentration (mmol/L) 7.3 (6-6-82) 7.2 (6.7-81) 0.83 Patients receiving insulin	Daily interruption of sedation			
Time on mechanical ventilation with DIS (%)†14% (5-33)20% (5-44)0.36Sedation and analgesia durationSedation duration (days) 2.7 (1.5-5-5) 4.3 (2.5-6.8)0.06Time on sedation (%)‡ 69% (27) 68% (27) 0.84 Opiate duration (days) 2.3 (1.3-4.3) 3.3 (1.7-6.1) 0.14 Time on opiate (%)‡ 65% (42-89) 71% (32-86) 0.64 Coma (days) 0.0 (0.0-0.2) 1.0 (0.0-3.0) 0.12 ICU days with coma (%) 0% (0.15) 8% (0-27) 0.21 Drug details, sedative and analgesic agentsPatients receiving propofol 48 (98%) 53 (96%) 1.0 Propofol dose (mg/h)99 (46-136)96 (53-141) 0.98 Patients receiving opiate 48 (98%) 54 (98%) 0.43 Lorazepam equivalents (mg/h) 2.6 (0.7-5.4) 3.1 (0.9-6.1) 0.83 Patients receiving banzodiazepine 39 (80%) 48 (87%) 0.43 Lorazepam equivalents (mg/h) 0.02 (0.0-0.3) 0.02 (0.0-0.0) 1.0 Mutrition and glycaemic control V V V Sustained ng per ady) 0.02 (0.0-0.3) 34% (15-58) 0.99 Blood glucose, morning concentration (mmol/L) 7.3 (6-6-82) 7.2 (6-7-8.1) 0.83 Patients receiving insulin infusion (%) 40 (82%) 54% (3%) 0.74 Sustained anxiety or agitation 69 (55%) 101 (57%) 0.78 Sustained pain $5(4\%)$ $5(3\%)$ 0	Days of sedation with DIS (%) *	100% (100–100)	100% (100–100)	0.56
Sedation and analgesia duration Sedation duration (days) 2.7 (1.5-5.5) 4.3 (2.5-6.8) 0.06 Time on sedation (%)‡ 69% (27) 68% (27) 0.84 Opiate duration (days) 2.3 (1.3-4.3) 3.3 (1.7-6.1) 0.14 Time on opiate (%)‡ 65% (42-89) 71% (32-86) 0.64 Coma (days) 0.0 (0-0-0.2) 1.0 (0-0-3.0) 0.12 ICU days with coma (%) 0% (0-15) 8% (0-27) 0.21 Drug details, sedative and analgesic agents 90 1.0 9.9 Patients receiving propofol 48 (98%) 53 (96%) 1.0 Propofol dose (mg/h) 99 (46-136) 96 (53-141) 0.98 Patients receiving opiate 48 (98%) 54 (98%) 1.0 Morphine equivalents (mg/h) 2.6 (0.7-5.4) 3.1 (0.9-6.1) 0.83 Patients receiving haloperidol 8 (16%) 9 (16%) 0.43 Lorazepam equivalents (mg/h) 0.02 (0.0-0.3) 0.02 (0.0-0.2) 0.89 Patients receiving haloperidol 8 (16%) 9 (16%) 0.83 Haloperidol (mg per day) 0.0 (0.0-0.0 1.0 0.93	Duration of DIS per patient (h per day)	2.7 (0.8-6.5)	3·3 (1·0–8·9)	0.35
Sedation duration (days) 2.7 (1.5-5.5) 4.3 (2.5-6.8) 0.06 Time on sedation (%)‡ 69% (27) 68% (27) 0.84 Opiate duration (days) 2.3 (1.3-4.3) 3.3 (1.7-6.1) 0.14 Time on opiate (%)‡ 65% (42-89) 71% (32-86) 0.64 Coma (days) 0.0 (0-0-02) 1.0 (0.0-3-0) 0.12 ICU days with coma (%) 0% (0-15) 8% (0-27) 0.21 Drug details, sedative and analgesic agents 71% (32-86) 0.64 Patients receiving propofol 48 (98%) 53 (96%) 1.0 Propofol dose (mg/h) 99 (46-136) 96 (53-141) 0.98 Patients receiving popate 48 (98%) 54 (98%) 1.0 Morphine equivalents (mg/h) 2.6 (0.7-5.4) 31 (0.9-6.1) 0.83 Lorazepam equivalents (mg/h) 0.02 (0.0-0.3) 0.02 (0.0-0.2) 0.89 Patients receiving haloperidol 8 (16%) 9 (16%) 0.83 Haloperidol (mg per day) 0 (0-0-0.0) $0.00 - 0.0$ 1.0 Bl	Time on mechanical ventilation with DIS (%)†	14% (5-33)	20% (5-44)	0.36
Time on sedation (%)‡69% (27)68% (27)0.84Opiate duration (days) 2.3 (13-4.3) 3.3 (17-6.1)0.14Time on opiate (%)‡65% (42-89)71% (32-86)0.64Coma (days)0.0 (0-0-0.2)1.0 (0-0-3.0)0.12ICU days with coma (%)0% (0-15)8% (0-27)0.21Drug dezils, sedative and analgesic agents96 (53-141)0.98Patients receiving propofol48 (98%)53 (96%)1.0Propofol dose (mg/h)99 (46-136)96 (53-141)0.98Patients receiving opiate48 (98%)54 (98%)0.43Morphine equivalents (mg/h)2.6 (0.7-5.4)3.1 (0.9-6.1)0.83Patients receiving benzodiazepine39 (80%)48 (87%)0.43Lorazepam equivalents (mg/h)0.02 (0.0-0.3)0.02 (0.0-0.2)0.89Patients receiving haloperidol8 (16%)9 (16%)0.80Haloperidol (mg per day)0 (0-0-00)0 (0-0-00)1.0Nutrition and glycaemic control100.830.99Blood glucose, morning concentration (mmol/L)7.3 (6-6-8.2)7.2 (6-7-8.1)0.83Patients receiving insulin infusion (%)40 (82%)42 (76%)0.68Sustained anxiety or agitation69 (55%)101 (57%)0.78Sustained pain5 (4%)5 (3%)0.74Oxygen saturation -88% for >5 min2 (2%)1660.36Reasons for unsuccessful spontaneous breathing tritter5 (4%)6 (34%)0.36Reasons for unsuccessful spontaneous	Sedation and analgesia duration			
Opiate duration (days) $2 \cdot 3(1 \cdot 3 - 4 \cdot 3)$ $3 \cdot 3(1 \cdot 7 - 61)$ $0 \cdot 14$ Time on opiate (%)‡ $65\% (42 - 89)$ $71\% (32 - 86)$ 0.64 Coma (days) $0 \cdot 0 \cdot 0 - 0 \cdot $	Sedation duration (days)	2.7 (1.5-5.5)	4.3 (2.5–6.8)	0.06
Time on opiate (%)‡ $65\% (42-89)$ $71\% (32-86)$ 04 Coma (days) $0 - 0 (0 - 0 - 0.2)$ $1 - 0 (0 - 0 - 3.0)$ 0.12 ICU days with coma (%) $0\% (0 - 15)$ $8\% (0 - 27)$ 0.21 Drug details, sedative and analgesic agentsPatients receiving propofol $48 (98\%)$ $53 (96\%)$ 1.0 Propofol dose (mg/h) $99 (46 - 136)$ $96 (53 - 141)$ 0.98 Patients receiving opiate $48 (98\%)$ $54 (98\%)$ 1.0 Morphine equivalents (mg/h) $2 \cdot 6 (0.7 - 5 \cdot 4)$ $3 \cdot 10 \cdot 9 - 6 \cdot 1$ 0.83 Patients receiving benzodiazepine $39 (80\%)$ $48 (87\%)$ 0.43 Lorazepam equivalents (mg/h) $0 \cdot 02 (0 - 0 - 3)$ $0 \cdot 02 (0 - 0 - 2)$ 0.89 Patients receiving haloperidol $8 (16\%)$ $9 \cdot 16\%$ 0.80 Haloperidol (mg per day) $0 \cdot 0 - 0 - 0$ $0 \cdot 0 - 0 - 0$ $1 \cdot 0$ Nutrition and glycaemic controlUSustained anxiety or agitation $57 \cdot (47 - 8 - 2)$ $7 \cdot 2 \cdot (6 - 7 - 8 - 1)$ 0.83 Patients receiving insulin infusion (%) $40 \cdot 82\%$ $42 \cdot (76\%)$ 0.68 Sustained anxiety or agitation $50 \cdot (4\%)$ $53 \cdot 3\%$ 0.74 Oxygen saturation <88% for $> 5 \cdot min$ $2 \cdot (2\%)$ $11 \cdot (6\%)$ 0.83 Sustained pain $5 \cdot (4\%)$ $5 \cdot (3\%)$ 0.74 Output $50 \cdot (4\%)$ $50 \cdot (2\%)$ 0.68 Sustained pain $5 \cdot (4\%)$	Time on sedation (%)‡	69% (27)	68% (27)	0.84
Coma (days) $0.0 (0.0-0.2)$ $1.0 (0.0-3.0)$ 0.12 ICU days with coma (%) $0\% (0-15)$ $8\% (0-27)$ 0.21 Drug details, sedative and analgesic agentsPatients receiving propofol $48 (98\%)$ $53 (96\%)$ 1.0 Propofol dose (mg/h) $99 (46-136)$ $96 (53-141)$ 0.98 Patients receiving opiate $48 (98\%)$ $54 (98\%)$ 1.0 Morphine equivalents (mg/h) $2.6 (0.7-5.4)$ $3.1 (0.9-6.1)$ 0.83 Patients receiving benzodiazepine $39 (80\%)$ $48 (87\%)$ 0.43 Lorazepam equivalents (mg/h) $0.02 (0.0-0.3)$ $0.02 (0.0-0.2)$ 0.89 Patients receiving haloperidol $8 (16\%)$ $9 (16\%)$ 0.80 Haloperidol (mg per day) $0 (0.0-0.0)$ $0 (0.0-0.0)$ 1.0 Nutrition and glycaemic control 1.0 $37\% (11-58)$ $34\% (15-58)$ 0.99 Blood glucose, morning concentration (mmol/L) $7.3 (6-6-8.2)$ $7.2 (6.7-8.1)$ 0.83 Patients receiving insulin infusion (%) $40 (82\%)$ $42 (76\%)$ 0.68 Blood glucose, morning concentration 100 0.53% 0.74 Sustained pain $5 (4\%)$ $5 (3\%)$ 0.78 Sustained pain $5 (4\%)$ $5 (3\%)$ 0.74 Oxygen saturation <88% for >5 min $2 (2\%)$ $11 (6\%)$ 0.68 The sepiratory rate <8 breaths per min for $\ge min$ $3 (2\%)$ $2 (2\%)$ 0.68 Oxygen saturation <88% for $\ge 5 min$ $3 (2\%)$ $2 (2\%)$ 0.68 Respiratory ra	Opiate duration (days)	2.3 (1.3-4.3)	3.3 (1.7-6.1)	0.14
ICU days with coma (%) 0% (0-15) 8% (0-27) 0.21 Drug details, sedative and analgesic agentsPatients receiving propofol 48 (98%) 53 (96%) 1.0 Propofol dose (mg/h) 99 (46-136) 96 (53-141) 0.98 Patients receiving opiate 48 (98%) 54 (98%) 1.0 Morphine equivalents (mg/h) 2.6 (0.7-5.4) 3.1 (0.9-6.1) 0.83 Patients receiving benzodiazepine 39 (80%) 48 (87%) 0.43 Lorazepam equivalents (mg/h) 0.02 (0.0-0.3) 0.02 (0.0-0.2) 0.89 Patients receiving haloperidol 8 (16%) 9 (16%) 0.80 Haloperidol (mg per day) 0 (0.0-0-00) 0 (0.0-0-00) 1.0 Nutrition and glycaemic control 7.3 (6-6-8.2) 7.2 (6.7-8.1) 0.83 Blood glucose, morning concentration (mmol/L) 7.3 (6-6-8.2) 7.2 (6.7-8.4) 0.83 Patients receiving insulin infusion (%) 40 (82%) 42 (76%) 0.68 Sustained anxiety or agitation 69 (55%) 101 (57%) 0.78 Sustained pain 5 (4%) 5 (3%) 0.74 Oxygen saturation <88% for >5 min 2 (2%) 16% 0.68 Teasons for unsuccessful spontaneous breathing tribute V V V Respiratory rate <8 breaths per min for ≥ 5 min 3 (2%) 2 (2%) 0.68 Oxygen saturation <88% for ≥ 5 min 5 (4%) 3 (2%) 0.72 Acute cardiac dysrlythmia 0 (0%) 11% 0.49 <td>Time on opiate (%)‡</td> <td>65% (42-89)</td> <td>71% (32–86)</td> <td>0.64</td>	Time on opiate (%)‡	65% (42-89)	71% (32–86)	0.64
Drug details, sedative and analgesic agentsPatients receiving propofol48 (98%)53 (96%)1-0Propofol dose (mg/h)99 (46-136)96 (53-141)0-98Patients receiving opiate48 (98%)54 (98%)1-0Morphine equivalents (mg/h)2-6 (0.7-5·4)3·1 (0-9-6·1)0-83Patients receiving benzodiazepine39 (80%)48 (87%)0-43Lorazepam equivalents (mg/h)0-02 (0-0-03)0-02 (0-0-02)0.89Patients receiving haloperidol8 (16%)9 (16%)0.80Haloperidol (mg per day)0 (0-0-00)0 (0-0-00)1.0Nutrition and glycaemic control37% (11-58)34% (15-58)0-99Blood glucose, morning concentration (mmol/L)7·3 (6-6-8·2)7·2 (6-7-8·1)0.83Patients receiving insulin infusion (%)40 (82%)42 (76%)0.68Sustained anxiety or agitation69 (55%)101 (57%)0.78Sustained pain5 (4%)5 (3%)0.740xygen saturation <88% for >5 min2 (2%)11 (6%)0.08Two or more signs of respiratory distress50 (40%)60 (34%)0.36Reasons for unsuccessful spontaneous breathing tritTwo or more signs of respiratory distress50 (40%)3 (2%)0.68Cuty of man of segation of set spinin2 (2%)0.68Cuty of man of segation of set spinin2 (2%)0.68Cuty of man of segation following intervSustained anxi	Coma (days)	0.0 (0.0-0.2)	1.0 (0.0-3.0)	0.12
Patients receiving propofol 48 (98%) 53 (96%) 1.0 Propofol dose (mg/h) 99 (46–136) 96 (53–141) 0-98 Patients receiving opiate 48 (98%) 54 (98%) 1.0 Morphine equivalents (mg/h) 2-6 (0.7–5.4) 3.1 (0.9–6.1) 0.83 Patients receiving benzodiazepine 39 (80%) 48 (87%) 0.43 Lorazepam equivalents (mg/h) 0-02 (0.0–0-3) 0.02 (0.0–0-2) 0.89 Patients receiving haloperidol 8 (16%) 9 (16%) 0.80 Haloperidol (mg per day) 0 (0-0–00) 0 (0-0–00) 1.0 Mutrition and glycaemic control 37% (11–58) 34% (15–58) 0-99 Blood glucose, morning concentration (mmol/L) 7.3 (6-6-8-2) 7.2 (6.7–8.1) 0.83 Patients receiving insulin infusion (%) 40 (82%) 42 (76%) 0.63 Blood glucose, morning concentration following interververververververververververververve	ICU days with coma (%)	0% (0-15)	8% (0-27)	0.21
Propofol dose (mg/h)99 (46-136)96 (53-141)0-98Patients receiving opiate48 (98%)54 (98%)1-0Morphine equivalents (mg/h)2-6 (0.7-5·4)3·1 (0-9-6·1)0.83Patients receiving benzodiazepine39 (80%)48 (87%)0-43Lorazepam equivalents (mg/h)0-02 (0-0-03)0-02 (0-0-02)0.89Patients receiving haloperidol8 (16%)9 (16%)0.80Haloperidol (mg per day)0 (0-0-00)0 (0-0-00)1.0Nutrition and glycaemic controlGoal calories given while intubated (%)37% (11-58)34% (15-58)0-99Blood glucose, morning concentration (mmol/L)7·3 (6-6-8-2)7·2 (6-7-8·1)0.83Patients receiving insulin infusion (%)40 (82%)42 (76%)0.68Sustained anxiety or agitation69 (55%)101 (57%)0.78Sustained pain5 (4%)5 (3%)0.74Oxygen saturation <88% for >5 min2 (2%)11 (6%)0.36Two or more signs of respiratory distress50 (40%)60 (34%)0.36Reasons for unsuccessful spontaneous breathing triFeasing of separatory distressSustained pain2 (2%)12 (2%)0.68Two or more signs of respiratory distress50 (40%)60 (34%)0.36Reasons for unsuccessful spontaneous breathing triFeasing of unsuccessful spontaneous breathing triReasons for unsuccessful spontaneous breathing triCalc%2 (2%)<	Drug details, sedative and analgesic agents			
Patients receiving opiate48 (98%)54 (98%)1.0Morphine equivalents (mg/h) 2.6 (0.7–5.4) 3.1 (0.9–6.1) 0.83 Patients receiving benzodiazepine 39 (80%) 48 (87%) 0.43 Lorazepam equivalents (mg/h) 0.02 (0.0–0.3) 0.02 (0.0–0.2) 0.89 Patients receiving haloperidol 8 (16%) 9 (16%) 0.80 Haloperidol (mg per day) 0 (0–0–0.0) 0 (0–0–0.0) 1.0 Nutrition and glycaemic controlGoal calories given while intubated (%) 37% (11–58) 34% (15–58) 0.99 Blood glucose, morning concentration (mmol/L) 7.3 (6–6–8-2) 7.2 (6–7–8-1) 0.83 Patients receiving insulin infusion (%) 40 (82%) 42 (76%) 0.68 Sustained anxiety or agitation 69 (55%) 101 (57%) 0.74 $0xgen saturation <88%$ for >5 min 2 (2%) 11 (6%) 0.36 Two or more signs of respiratory distress 50 (40%) 60 (34%) 0.36 Reasons for unsuccessful spontaneous breathing triTwo or more signs of respiratory distress 50 (40%) 60 (34%) 0.36 Reasons for unsuccessful spontaneous breathing triTwo or more signs of respiratory distress 50 (40%) $3(2\%)$ 0.68 Oxygen saturation <88% for ≥ 5 min $3(2\%)$ $2(2\%)$ 0.68 Oxygen saturation <88% for ≥ 5 min $3(2\%)$ $2(2\%)$ 0.68 Oxygen satura	Patients receiving propofol	48 (98%)	53 (96%)	1.0
Morphine equivalents (mg/h) 2·6 (0.7-5·4) 3·1 (0.9-6·1) 0·83 Patients receiving benzodiazepine 39 (80%) 48 (87%) 0·43 Lorazepam equivalents (mg/h) 0·02 (0·0-0·3) 0·02 (0·0-0·2) 0·89 Patients receiving haloperidol 8 (16%) 9 (16%) 0.80 Haloperidol (mg per day) 0 (0·0-0·0) 0 (0·0-0·0) 1.0 Nutrition and glycaemic control Goal calories given while intubated (%) 37% (11–58) 34% (15–58) 0·99 Blood glucose, morning concentration (mmol/L) 7·3 (6·6-8·2) 7·2 (6·7-8·1) 0.83 Patients receiving insulin infusion (%) 40 (82%) 42 (76%) 0.68 Reasons for resumption of sedation following interviens 5 0.99 0.74 Sustained pain 5 (4%) 5 (3%) 0.74 Oxygen saturation <88% for >5 min 2 (2%) 11 (6%) 0.83 Two or more signs of respiratory distress 50 (40%) 60 (34%) 0.36 Reasons for unsuccessful spontaneous breathitger H 2 (2%) 0.68 Oxygen saturation <88% for ≥5 min <td>Propofol dose (mg/h)</td> <td>99 (46–136)</td> <td>96 (53–141)</td> <td>0.98</td>	Propofol dose (mg/h)	99 (46–136)	96 (53–141)	0.98
Patients receiving benzodiazepine 39 (80%) 48 (87%) 0-43 Lorazepam equivalents (mg/h) 0-02 (0-0-0.3) 0-02 (0-0-0.2) 0-89 Patients receiving haloperidol 8 (16%) 9 (16%) 0-80 Haloperidol (mg per day) 0 (0-0-0.0) 0 (0-0-0.0) 1.0 Nutrition and glycaemic control Nutrition and glycaemic control Solution and glycaemic control Solutanot glycaemit following int <	Patients receiving opiate	48 (98%)	54 (98%)	1.0
Lorazepam equivalents (mg/h) 0.02 (0.0-0.3) 0.02 (0.0-0.2) 0.89 Patients receiving haloperidol 8 (16%) 9 (16%) 0.80 Haloperidol (mg per day) 0 (0-0-0.0) 0 (0-0-0.0) 1.0 Nutrition and glycaemic control Fatients receiving insulin intubated (%) 37% (11-58) 34% (15-58) 0.99 Blood glucose, morning concentration (mmol/L) 7.3 (6.6-8·2) 7.2 (6.7-8·1) 0.83 Patients receiving insulin infusion (%) 40 (82%) 42 (76%) 0.68 Sustained anxiety or agitation 69 (55%) 101 (57%) 0.78 Sustained pain 5 (4%) 5 (3%) 0.74 Oxygen saturation <88% for >5 min 2 (2%) 11 (6%) 0.08 Two or more signs of respiratory distress 50 (40%) 60 (34%) 0.36 Reasons for unsuccessful spontaneous breathing tribute US A (2%) 2 (2%) 0.68 Oxygen saturation <88% for ≥5 min	Morphine equivalents (mg/h)	2.6 (0.7–5.4)	3.1 (0.9-6.1)	0.83
Patients receiving haloperidol 8 (16%) 9 (16%) 0.80 Haloperidol (mg per day) 0 (0-0-0) 0 (0-0-0) 1-0 Nutrition and glycaemic control 9 100 1-0 Goal calories given while intubated (%) 37% (11-58) 34% (15-58) 0-99 Blood glucose, morning concentration (mmol/L) 7.3 (6-6-8-2) 7.2 (6-7-8.1) 0-83 Patients receiving insulin infusion (%) 40 (82%) 42 (76%) 0-68 Reasons for resumption of sedation following interververververververververververververve	Patients receiving benzodiazepine	39 (80%)	48 (87%)	0.43
Haloperidol (mg per day) 0 (0.0–0.0) 0 (0.0–0.0) 1.0 Nutrition and glycaemic controlGoal calories given while intubated (%) 37% (11–58) 34% (15–58) 0.99 Blood glucose, morning concentration (mmol/L) 7.3 (6.6–8.2) 7.2 (6.7–8.1) 0.83 Patients receiving insulin infusion (%) 40 (82%) 42 (76%) 0.68 Reasons for resumption of sedation following interretrorsSustained anxiety or agitation 69 (55%) 101 (57%) 0.78 Sustained pain 5 (4%) 5 (3%) 0.74 Oxygen saturation <88% for >5 min 2 (2%) 11 (6%) 0.86 Two or more signs of respiratory distress 50 (40%) 60 (34%) 0.36 Reasons for unsuccessful spontaneous breathing tritter V V Respiratory rate <8 breaths per min for ≥ 5 min 3 (2%) 2 (2%) 0.68 Oxygen saturation <88% for ≥ 5 min 5 (4%) 3 (2%) 0.72 Acute cardiac dysrhythmia 0 (0%) 1 (1%) 0.49	Lorazepam equivalents (mg/h)	0.02 (0.0-0.3)	0.02 (0.0-0.2)	0.89
Nutrition and glycaemic control Goal calories given while intubated (%) 37% (11–58) 34% (15–58) 0.99 Blood glucose, morning concentration (mmol/L) 7.3 (6.6–8.2) 7.2 (6.7–8.1) 0.83 Patients receiving insulin infusion (%) 40 (82%) 42 (76%) 0.68 Reasons for resumption of sedation following interruptions Sustained anxiety or agitation 69 (55%) 101 (57%) 0.78 Sustained pain 5 (4%) 5 (3%) 0.74 Oxygen saturation <88% for >5 min 2 (2%) 11 (6%) 0.08 Two or more signs of respiratory distress 50 (40%) 60 (34%) 0.36 Reasons for unsuccessful spontaneous breathing trial/ Z Z 0.68 Oxygen saturation <88% for ≥5 min	Patients receiving haloperidol	8 (16%)	9 (16%)	0.80
Goal calories given while intubated (%) 37% (11–58) 34% (15–58) 0.99 Blood glucose, morning concentration (mmol/L) 7.3 (6.6–8.2) 7.2 (6.7–8.1) 0.83 Patients receiving insulin infusion (%) 40 (82%) 42 (76%) 0.68 Reasons for resumption of sedation following interrutions Sustained anxiety or agitation 69 (55%) 101 (57%) 0.78 Sustained anxiety or agitation 59 (4%) 5 (3%) 0.74 Oxygen saturation <88% for >5 min 2 (2%) 11 (6%) 0.08 Two or more signs of respiratory distress 50 (40%) 60 (34%) 0.36 Reasons for unsuccessful spontaneous breathing triature Respiratory rate <8 breaths per min for ≥5 min	Haloperidol (mg per day)	0 (0.0–0.0)	0 (0.0-0.0)	1.0
Blood glucose, morning concentration (mmol/L) 7.3 (6.6–8.2) 7.2 (6.7–8.1) 0.83 Patients receiving insulin infusion (%) 40 (82%) 42 (76%) 0.68 Reasons for resumption of sedation following interrutions Sustained anxiety or agitation 69 (55%) 101 (57%) 0.78 Sustained pain 5 (4%) 5 (3%) 0.74 Oxygen saturation <88% for >5 min 2 (2%) 11 (6%) 0.08 Two or more signs of respiratory distress 50 (40%) 60 (34%) 0.36 Reasons for unsuccessful spontaneous breathing triature Respiratory rate <8 breaths per min for ≥5 min	Nutrition and glycaemic control			
Patients receiving insulin infusion (%)40 (82%)42 (76%)0-68Reasons for resumption of sedation following interruption\$Sustained anxiety or agitation69 (55%)101 (57%)0-78Sustained pain5 (4%)5 (3%)0-74Oxygen saturation <88% for >5 min2 (2%)11 (6%)0-08Two or more signs of respiratory distress50 (40%)60 (34%)0-36Reasons for unsuccessful spontaneous breathing trial¶Respiratory rate <8 breaths per min for ≥5 min	Goal calories given while intubated (%)	37% (11–58)	34% (15-58)	0.99
Reasons for resumption of sedation following interruption\$Sustained anxiety or agitation69 (55%)101 (57%)0.78Sustained pain5 (4%)5 (3%)0.74Oxygen saturation <88% for >5 min2 (2%)11 (6%)0.08Two or more signs of respiratory distress50 (40%)60 (34%)0.36Reasons for unsuccessful spontaneous breathing trial¶Respiratory rate <8 breaths per min for ≥5 min	Blood glucose, morning concentration (mmol/L)	7.3 (6.6-8.2)	7.2 (6.7-8.1)	0.83
Sustained anxiety or agitation $69 (55\%)$ $101 (57\%)$ 0.78 Sustained pain $5 (4\%)$ $5 (3\%)$ 0.74 Oxygen saturation <88% for >5 min $2 (2\%)$ $11 (6\%)$ 0.08 Two or more signs of respiratory distress $50 (40\%)$ $60 (34\%)$ 0.36 Reasons for unsuccessful spontaneous breathing trial¶ Respiratory rate <8 breaths per min for ≥5 min	Patients receiving insulin infusion (%)	40 (82%)	42 (76%)	0.68
Sustained pain 5 (4%) 5 (3%) 0.74 Oxygen saturation <88% for >5 min 2 (2%) 11 (6%) 0.08 Two or more signs of respiratory distress 50 (40%) 60 (34%) 0.36 Reasons for unsuccessful spontaneous breathing trial¶Respiratory rate <8 breaths per min for ≥5 min	Reasons for resumption of sedation following inte	rruption§		
Oxygen saturation <88% for >5 min2 (2%)11 (6%)0.08Two or more signs of respiratory distress50 (40%)60 (34%)0.36Reasons for unsuccessful spontaneous breathing trial¶Respiratory rate <8 breaths per min for ≥5 min	Sustained anxiety or agitation	69 (55%)	101 (57%)	0.78
Two or more signs of respiratory distress50 (40%)60 (34%)0.36Reasons for unsuccessful spontaneous breathing trial¶Respiratory rate <8 breaths per min for ≥5 min	Sustained pain	5 (4%)	5 (3%)	0.74
Reasons for unsuccessful spontaneous breathing trial¶Respiratory rate <8 breaths per min for ≥ 5 min3 (2%)2 (2%)0.68Oxygen saturation <88% for ≥ 5 min5 (4%)3 (2%)0.72Acute cardiac dysrhythmia0 (0%)1 (1%)0.49	Oxygen saturation <88% for >5 min	2 (2%)	11 (6%)	0.08
Respiratory rate <8 breaths per min for ≥ 5 min 3 (2%) 2 (2%) 0.68 Oxygen saturation <88% for ≥ 5 min 5 (4%) 3 (2%) 0.72 Acute cardiac dysrhythmia 0 (0%) 1 (1%) 0.49	Two or more signs of respiratory distress	50 (40%)	60 (34%)	0.36
Oxygen saturation <88% for ≥5 min 5 (4%) 3 (2%) 0.72 Acute cardiac dysrhythmia 0 (0%) 1 (1%) 0.49	Reasons for unsuccessful spontaneous breathing tr	ial¶		
Acute cardiac dysrhythmia0 (0%)1 (1%)0-49	Respiratory rate <8 breaths per min for ≥5 min	3 (2%)	2 (2%)	0.68
	Oxygen saturation <88% for ≥5 min	5 (4%)	3 (2%)	0.72
Two or more signs of respiratory distress 127 (94%) 126 (95%) 0.82	Acute cardiac dysrhythmia	0 (0%)	1 (1%)	0.49
	Two or more signs of respiratory distress	127 (94%)	126 (95%)	0.82

Data are median (IQR), mean (SD), or n (%). DIS=daily interruption of sedation. ICU=intensive care unit. *Eligible days began 36 h following start of mechanical ventilation. †Total duration of sedative and analgesic interruption (h) divided by duration of mechanical ventilation (h). ‡Proportion of hours undergoing continuous sedative/opiate infusion versus total duration of mechanical ventilation (h). \$Resumption of sedation following interruption occurred 126 and 177 times in the intervention and control groups, respectively. Patients may have had more than one event. ¶Unsuccessful spontaneous breathing trials occurred 135 and 132 times in the intervention and control groups, respectively. Patients may have had more than one event.

Table 2: Therapy details and protocol adherence according to study group

regression model with return to independent function as the dependent variable.

We used GraphPad Prism software (version 5.0) for all statistical analyses apart from the Cox regression analysis, which was done with SPSS software (version 8.0). An independent biostatistician reanalysed the final dataset and verified all our results. Significant differences between groups or across time were reported at the alpha level of 0.05. All reported p values are two-sided. This trial is registered with ClinicalTrials.gov, number NCT00322010.

	Intervention (n=49)	Control (n=55)	p value
Return to independent functional status at hospital discharge	29 (59%)	19 (35%)	0.02
ICU delirium (days)	2.0 (0.0-6.0)	4.0 (2.0–7.0)	0.03
Time in ICU with delirium (%)	33% (0–58)	57% (33-69)	0.02
Hospital delirium (days)	2.0 (0.0-6.0)	4.0 (2.0-8.0)	0.02
Hospital days with delirium (%)	28% (26)	41% (27)	0.01
Barthel Index score at hospital discharge	75 (7·5–95)	55 (0-85)	0.05
ICU-acquired paresis at hospital discharge	15 (31%)	27 (49%)	0.09
Ventilator-free days*	23.5 (7.4–25.6)	21.1 (0.0–23.8)	0.05
Duration of mechanical ventilation (days)	3·4 (2·3–7·3)	6.1 (4.0-9.6)	0.02
Duration of mechanical ventilation, survivors (days)	3.7 (2.3-7.7)	5.6 (3.4–8.4)	0.19
Duration of mechanical ventilation, non-survivors (days)	2.5 (2.4–5.5)	9.5 (5.9–14.1)	0.04
Length of stay in ICU (days)	5.9 (4.5–13.2)	7.9 (6.1–12.9)	0.08
Length of stay in hospital (days)	13.5 (8.0–23.1)	12.9 (8.9–19.8)	0.93
Hospital mortality	9 (18%)	14 (25%)	0.53

Data are n (%), median (IQR), or mean (SD). ICU=intensive care unit. *Ventilator-free days from study day 1 to day 28 Barthel Index scale 0–100, APACHE II scale 0–71.

Table 3: Main outcomes according to study group




Figure 2: Probability of return to independent functional status in intervention and control groups

Role of the funding source

There was no funding source for this study. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Results

From June, 2005, to October, 2007, 1161 patients were screened, of whom 104 were enrolled and randomised. Figure 1 shows the trial profile. Nine (18%) patients in the intervention group and 14 (25%) patients in the

control group died before hospital discharge. All 104 patients were included in the intention-to-treat population. Table 1 shows the baseline characteristics of the enrolled patients.

Of the 49 patients in the intervention group, 46 (94%) underwent physical and occupational therapy (three died before any intervention). For the intervention patients as a group, therapy occurred on 87% of days on study. There are three reasons why therapy did not occur all of the time: (1) the patient was unstable (defined by criteria listed in the Methods section); (2) the patient was unavailable for therapy (competing procedure or travel for intervention or test outside of the ICU); and (3) goals of care were changed to comfort measures only.

The median duration of physical and occupational therapy during mechanical ventilation differed between groups (intervention 0.32 h per day, IQR 0.17-0.48; control 0.0 h per day, 0.0-0.0; p<0.0001). Patients in the intervention group underwent therapy at a median of 1.5 days (1.0-2.1) after intubation whereas controls had therapy initiated at 7.4 days (6.0-10.9) after intubation (p<0.0001). However, time to therapy for patients in the control group was shorter than the median length of stay in the ICU (7.9 days, 6.1-12.9). The median duration of physical and occupational therapy during the time not receiving mechanical ventilation was similar between groups (intervention 0.21 h per day, 0.08-0.33; control 0.19 h per day, 0.0-0.38; p=0.70). Of 22 patients in the control group who were extubated and survived to hospital discharge but never returned to independent functional status, 21 (95%) underwent therapy.

Sedation and analgesia practice did not differ between groups, including occurrence and duration of daily interruption of sedation and proportion of time on mechanical ventilation that was spent receiving sedative or opiate. However, total sedation duration was longer in controls than in patients in the intervention group, which reflects the difference in duration of mechanical ventilation between the groups (table 2). Reasons and occurrence rates for resumption of sedation were similar for both groups.3 Both groups had very high spontaneous breathing trial performance rates on days when this screen was passed (intervention 200 [96%] of 209); control 197 [98%] of 201). Reasons and occurrence rates for unsuccessful spontaneous breathing trials were also similar between groups.3 All 104 patients received enteral nutrition only, and both groups were similar with regard to goal calories given while intubated, median morning glucose concentration, and proportion of patients receiving insulin (table 2).

Return to independent functional status at hospital discharge occurred in more patients in the intervention group than in the control group (29 [59%] patients vs 19 [35%] patients; p=0.02; odds ratio 2.7 [95% CI 1.2–6.1]; table 3). A log-rank (survival) analysis for return to independent functional status confirmed this

observation (figure 2), and showed that the effect of the intervention is delayed by approximately 2 weeks. Variables associated with achievement of functional independence by Cox proportional hazards analysis were age (hazard ratio [HR] 0.96, 95% CI 0.94-0.98; p=0.001), absence of sepsis (HR 2.26, 1.03-4.97; p=0.04] and the intervention (HR 1.84, 1.02-3.31; p=0.04). No association was detected with APACHE II score (HR 0.97, 0.92-1.02; p=0.22). There was no significant interaction between study centre and treatment with regard to the primary endpoint (data not shown).

Patients in the intervention group had higher Barthel Index scores (table 3), a higher number of independent ADLs (table 4), and greater unassisted walking distance at hospital discharge than did controls (table 4). ICUacquired paresis (MRC examination score <48) was noted at hospital discharge in 15 (31%) patients in the intervention group and in 27 (49%) controls (p=0.09). Figure 3 shows rates of independence with individual ADLs and walking. Median MRC examination score and hand-grip strength at hospital discharge did not differ between groups (table 4). Patients in the intervention group were able to achieve several activity milestones during mechanical ventilation, such as sitting at the side of the bed (38 patients [78%]), standing (25 patients [51%]), marching in place (13 patients [27%]), transferring to a chair (21 patients [43%]), walking two steps or more (12 patients [24%]), and walking more than 30.5 m (three patients [6%]).

The subsequent locations of patients after hospital discharge are shown in table 5. The median duration of ICU-associated delirium was half as long in patients in the intervention group than in controls despite no differences in sedation (table 3). Additionally, patients in the intervention group spent a median of $2 \cdot 4$ more days alive and breathing without ventilatory support (ventilator-free days). Length of stay in the ICU and in hospital did not differ between groups (table 3).

Serious adverse events were uncommon: one event in 498 physical and occupational therapy sessions (one desaturation less than 80%).¹² There were no extubations, falls, or systolic blood pressure changes less than 90 mm Hg or more than 200 mm Hg. Additionally, one radial arterial catheter was inadvertently removed in the intervention group. Discontinuation of therapy as a result of patient instability occurred in 19 (4%) of all sessions, most commonly for perceived patient-ventilator asynchrony.

Discussion

In this randomised controlled trial, daily interruption of sedation combined with physical and occupational therapy from the start of critical illness in patients on mechanical ventilation resulted in an improved return to (premorbid) independent functional status at hospital discharge compared with daily interruption of sedation and standard care. Additionally, patients in the inter-

	Intervention (n=49)	Control (n=55)	p value
Time from intubation to first PT/OT session (days)	1.5 (1.0–2.1)	7.4(6.0-10.9)	<0.0001
Independent ADLs total at ICU discharge	3 (0–5)	0 (0–5)	0.15
Independent ADLs total at hospital discharge	6 (0–6)	4 (0-6)	0.06
MRC examination score at hospital discharge	52 (25-58)	48 (0–58)	0.38
Hand-grip strength at hospital discharge (kg-force)	39 (10–58)	35 (0–57)	0.67
Greatest walking distance at hospital discharge (m)	33.4 (0-91.4)	0 (0-30-4)	0.004
Time from intubation to milestones achieved (days)			
Out of bed	1.7 (1.1–3.0)	6.6 (4.2-8.3)	<0.0001
Standing	3.2 (1.5–5.6)	6.0 (4.5-8.9)	<0.0001
Marching in place	3.3 (1.6–5.8)	6-2 (4-6-9-6)	<0.0001
Transferring to a chair	3.1 (1.8–4.5	6-2 (4-5-8-4)	<0.0001
Walking	3.8 (1.9–5.8)	7·3 (4·9–9·6)	<0.0001

Data are median (IQR). ADLs=activities of daily living. ICU=intensive care unit. MRC=Medical Research Council. PT/OT=physical therapy and occupational therapy. MRC examination scale 0–60.

Table 4: Function and muscle strength outcomes according to study group




Figure 3: Proportion of patients able to perform activities of daily living and to walk independently at hospital discharge

vention group had a shorter duration of ICU-associated delirium by $2 \cdot 0$ days and spent $2 \cdot 4$ more days alive and breathing without assistance than did controls. Early physical and occupational therapy, combined with daily interruption of sedation, was safe and well tolerated. Thus, this trial shows that both functional and psychological outcomes of patients on mechanical ventilation can be improved by the implementation of physical and occupational therapy in the earliest phases of critical illness. However, in this study, these outcomes did not translate into any difference in length of stay in

	Intervention (n=49)	Control (n=55)
Home*	21 (43%)	13 (24%)
Acute rehabilitation	13 (27%)	17 (31%)
Subacute rehabilitation	0 (0%)	6 (11%)
Long-term rehabilitation	5 (10%)	3 (5%)
Nursing home	1 (2%)	1(2%)
Hospice	0 (0%)	1 (2%)
Death	9 (18%)	14 (25%)
*p=0.06 for comparison of ho comparison of both groups.	me discharge to all other p	ossible locations for the

Table 5: Subsequent location of patients after hospital discharge

the ICU or in hospital between intervention and control groups.

As critical illness incidence and survival increase, issues surrounding ICU recovery will affect many patients. Investigations have highlighted the substantial morbidity and mortality and increased health-care needs associated with ICU-acquired weakness and neuropsychiatric illness in survivors of critical illness.432-34 Deep sedation and immobility might potentiate these complications, especially ICU-acquired weakness.³⁵ DeJonghe and colleagues²⁹ found that duration of mechanical ventilation before awakening to establish the diagnosis of ICU-acquired paresis was a risk factor for the presence of the condition, independent of the duration of multiple organ failure. Repeated daily passive mobilisation prevents muscle atrophy in mechanically ventilated patients receiving neuromuscular blocking agents.³⁶ Finally, studies have shown that keeping sedation to a minimum reduces the rate of ICU-related complications.37,38

The adverse effects of skeletal muscle immobility are well recognised; atrophic processes begin within 72 h and even healthy, well-nourished individuals can show loss in muscle mass and strength within 10 days of bed rest.^{39,40} Furthermore, the loss of independence during acute hospital admission can be profound, even in the absence of critical illness.^{41,42} Accordingly, mobilisation is prescribed to maximise return to independence and avoid complications of atelectasis, pressure wounds, indwelling catheters, and delirium.43,44 However, mechanical ventilation and sedation displace these therapies from routine practice in the earliest days of critical illness. In this study, we implemented daily interruption of sedation combined with mobilisation done within 48 h of the start of critical care; this method is distinct from previous studies of mobilisation. This study shows the safety of this early intervention and quantifies clinical benefit.

Delirium and neuromuscular function are undoubtedly linked. Without intact cognition, physical activity is either self-limited or iatrogenically limited, cooperation with therapy is poor, and any immobilisation injury is likely to be exacerbated. Patients in post-acute care with persistent delirium have shown poor functional recovery.⁴⁵ In non-ICU inpatients, development of delirium during hospital admission is associated with a raised subsequent risk of cognitive impairment or dementia. The relation between the duration of ICU-associated delirium and chronic or permanent cognitive impairment is complex; limited data suggest such an association.⁴⁶ These functional and cognitive impairments might provide the most likely reason for the excess longer-term mortality associated with delirium.⁷⁴⁷

Sedative-induced immobility is a preventable contributor to ICU-acquired weakness and functional impairment. However, other factors exist, including systemic inflammation (particularly sepsis), age, drugs, and severity of illness. As shown in this study, sepsis and age were independently associated with functional dependence. Beyond simply reversing immobility, another factor might have contributed to the success of the intervention. Because there were substantial differences between functional measurements despite no significant difference in absolute MRC examination or hand-grip strength scores between groups, it is possible that patients had a learning effect. Indeed, learning to function independently despite weakness is a goal of physical and occupational therapy.

The nature of the intervention prevented any blinding from patient and health-care providers, and knowledge of group allocation and witnessed interventions risk bias of study results. To address this drawback, we randomly assigned patients to treatment groups and managed them with daily interruption of sedation, daily spontaneous breathing trials, strict glycaemic control, and balanced nutritional intake between groups during the course of mechanical ventilation. Most importantly, serial assessments were done in a manner to maintain blinding of the assessor. However, decisions about sedation initiation or reinitiation, extubation, and ICU and hospital discharge were not controlled by protocol and might have been affected by knowledge of the intervention. However, we noted no differences between groups in indication for sedation reinitiation and spontaneous breathing trial failure or performance rates. Furthermore, the post-ICU hospital admission duration reported for both groups in this study accord with findings from a cohort study of mobilisation.14

Rates and timing of physical and occupational therapy and nursing behaviours might have been additionally affected (in either direction) by other confounding factors. The data show that neither centre routinely performs physical and occupational therapy in patients who receive mechanical ventilation for less than 2 weeks without a developing neuromuscular disease. Although it is possible that other ICUs might practise more aggressive early physical or occupational therapy than our control group, we were able to find little evidence of such practice in the published literature.⁴⁸ Furthermore, recent studies highlight the infrequency of physical therapy in the ICU.^{14,49} For example, in a standard care group within a single-centre study directed at promoting the mobility of critically ill patients, only 47% of patients received physical therapy at any time during their hospital stay, and only 6% of patients received physical therapy at any time in the ICU.14 In our study, patients in the control group for whom consultation of physical and occupational therapy would be typical (ie, extubated survivors unable to perform ADLs and unable to walk) received therapy 95% of the time. The median duration of therapy for patients not undergoing mechanical ventilation was similar between groups. These findings, together with a median time to therapy earlier than ICU discharge, suggest that the treatment given to the control group was a fair representation of routine care, and identify the very early ICU therapy as the difference between groups. The work by our group and by others¹²⁻¹⁴ supports the feasibility and safety of early mobilisation in patients on mechanical ventilation in intensive care. Our study shows the benefits of this intervention on restoration of functional independence as well as delirium reduction. The trend towards better discharge rates to home (intervention 43% vs control 24%; p=0.06 for comparison of home discharge to all other possible locations for the comparison of both groups) is intriguing. We now need to determine whether early mobilisation in intensive care can enhance successful home discharge and reduce the burden of post-ICU rehabilitative care.

The results of this study cannot be assumed to be directly applicable to all patients on mechanical ventilation. This is a select population of patients—critically ill, yet independent in premorbid health. Trial enrolment rates reflect the selective nature of these patients, yet their baseline functional independence was necessary to prove the prevention of functional loss. Physical and occupational therapy probably cannot result in a functional status after critical illness that surpasses baseline health. The relation of improved functional status at hospital discharge with long-term outcomes in this population is unclear. Studies in patients with chronic obstructive lung disease, patients with traumatic brain injury, and in elderly hospital inpatients suggest connections with improved morbidity, quality of life, and survival.^{41,50-53}

Thus, a strategy for whole-body rehabilitation accomplished by interruption of sedation, protocoldriven spontaneous breathing trials, and physical and occupational therapy—resulted in better outcomes compared with current standard approaches to sedation and activity during mechanical ventilation and its recovery. Patients assigned to intervention had shorter duration of delirium and left the hospital with better functional status. This study highlights the robust outcomes that can be achieved with the coordinated efforts of multiple disciplines dedicated to the survival and mental and physical recovery of critically ill patients receiving mechanical ventilation.

Contributors

WDS, ASP, CN, JBH, and JPK participated in the conception of the trial. WDS, ASP, CN, AJP, CLE, LS, MM, MF, DD, JBH, and JPK participated in study design. WDS, MCP, ASP, CN, GAS, AB, KEM, and JPK recruited patients and collected data; AJP, CLE, LS, MM, MF, DD, and RB collected data alone. WDS, MCP, ASP, GAS, KEM, JBH, and JPK analysed the data. All authors participated in interpretation of the results. WDS drafted the manuscript, and all authors contributed to critical review and revision of the manuscript. All authors have seen and approved the final version of the manuscript.

Conflicts of interest

We declare that we have no conflicts of interest.

Acknowledgments

We thank the ICU staff at the University of Chicago Medical Center and the University of Iowa Hospital for their invaluable participation in this study.

References

- Kress JP, Pohlman AS, O'Connor MF, Hall JB. Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. N Engl J Med 2000; 342: 1471–77.
- 2 Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. *N Engl J Med* 2000; 342: 1301–08.
- 3 Girard TD, Kress JP, Fuchs BD, et al. Efficacy and safety of a paired sedation and ventilator weaning protocol for mechanically ventilated patients in intensive care (Awakening and Breathing Controlled trial): a randomised controlled trial. *Lancet* 2008; 371: 126–34.
- 4 Herridge MS, Cheung AM, Tansey CM, et al. One-year outcomes in survivors of the acute respiratory distress syndrome. N Engl J Med 2003; 348: 683–93.
- 5 De Jonghe B, Lacherade JC, Durand MC, Sharshar T. Critical illness neuromuscular syndromes. *Crit Care Clin* 2007; 23: 55–69.
- Schweickert WD, Hall J. ICU-acquired weakness. Chest 2007; 131: 1541–49.
- ⁷ Ely EW, Shintani A, Truman B, et al. Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. *JAMA* 2004; **291**: 1753–62.
- 8 Ely EW, Gautam S, Margolin R, et al. The impact of delirium in the intensive care unit on hospital length of stay. *Intensive Care Med* 2001; 27: 1892–900.
- Kress JP, O'Connor MF, Pohlman AS, et al. Sedation of critically ill patients during mechanical ventilation. A comparison of propofol and midazolam. *Am J Respir Crit Care Med* 1996; 153: 1012–18.
- 10 Weinert CR, Calvin AD. Epidemiology of sedation and sedation adequacy for mechanically ventilated patients in a medical and surgical intensive care unit. *Crit Care Med* 2007; 35: 393–401.
- Schweickert WD, Kress JP. Strategies to optimize analgesia and sedation. Crit Care 2008; 12 (suppl 3): S6.
- 12 Bailey P, Thomsen GE, Spuhler VJ, et al. Early activity is feasible and safe in respiratory failure patients. *Crit Care Med* 2007; **35**: 139–45.
- 13 Thomsen GE, Snow GL, Rodriguez L, Hopkins RO. Patients with respiratory failure increase ambulation after transfer to an intensive care unit where early activity is a priority. *Crit Care Med* 2008; 36: 1119–24.
- 14 Morris PE, Goad A, Thompson C, et al. Early intensive care unit mobility therapy in the treatment of acute respiratory failure. *Crit Care Med* 2008; 36: 2238–43.
- 15 Pun BT, Ely EW. The importance of diagnosing and managing ICU delirium. Chest 2007; 132: 624–36.
- 16 Riker RR, Shehabi Y, Bokesch PM, et al. Dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial. *JAMA* 2009; **301**: 489–99.
- 17 Mahoney FI, Barthel DW. Functional evaluation: the Barthel Index. Md State Med J 1965; 14: 61–65.
- 18 Collin C, Wade DT, Davies S, Horne V. The Barthel ADL Index: a reliability study. Int Disabil Stud 1988; 10: 61–63.
- 19 Sessler CN, Gosnell MS, Grap MJ, et al. The Richmond Agitation-Sedation Scale: validity and reliability in adult intensive care unit patients. Am J Respir Crit Care Med 2002; 166: 1338–44.

- 20 Ely EW, Truman B, Shintani A, et al. Monitoring sedation status over time in ICU patients: reliability and validity of the Richmond Agitation-Sedation Scale (RASS). JAMA 2003; 289: 2983–91.
- 21 Ely EW, Inouye SK, Bernard GR, et al. Delirium in mechanically ventilated patients: validity and reliability of the confusion assessment method for the intensive care unit (CAM-ICU). *JAMA* 2001; **286**: 2703–10.
- 22 Ely EW, Margolin R, Francis J, et al. Evaluation of delirium in critically ill patients: validation of the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU). *Crit Care Med* 2001; **29**: 1370–79.
- 23 van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001; 345: 1359–67.
- 24 Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. Studies of illness in the aged. The index of ADL: a standardized measure of biological and psychosocial function. *JAMA* 1963; 185: 914–19.
- 25 Katz S, Akpom CA. 12. Index of ADL. *Med Care* 1976; 14: 116–18.
- 26 Ip SP, Leung YF, Ip CY, Mak WP. Outcomes of critically ill elderly patients: is high-dependency care for geriatric patients worthwhile? *Crit Care Med* 1999; 27: 2351–57.
- 27 Bigatello LM, Stelfox HT, Berra L, Schmidt U, Gettings EM. Outcome of patients undergoing prolonged mechanical ventilation after critical illness. *Crit Care Med* 2007; 35: 2491–97.
- 28 Keith RA, Granger CV, Hamilton BB, Sherwin FS. The functional independence measure: a new tool for rehabilitation. *Adv Clin Rehabil* 1987; 1: 6–18.
- 29 De Jonghe B, Sharshar T, Lefaucheur JP, et al. Paresis acquired in the intensive care unit: a prospective multicenter study. JAMA 2002; 288: 2859–67.
- 30 Kleyweg RP, van der Meche FG, Meulstee J. Treatment of Guillain-Barre syndrome with high-dose gammaglobulin. *Neurology* 1988; 38: 1639–41.
- 31 Kleyweg RP, van der Meche FG, Schmitz PI. Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barre syndrome. *Muscle Nerve* 1991; 14: 1103–09.
- 32 Cheung AM, Tansey CM, Tomlinson G, et al. Two-year outcomes, health care use, and costs of survivors of acute respiratory distress syndrome. Am J Respir Crit Care Med 2006; 174: 538–44.
- 33 Angus DC, Musthafa AA, Clermont G, et al. Quality-adjusted survival in the first year after the acute respiratory distress syndrome. Am J Respir Crit Care Med 2001; 163: 1389–94.
- 34 Ali NA, O'Brien JM, Hoffmann SP, et al. Acquired weakness, handgrip strength, and mortality in critically ill patients. *Am J Respir Crit Care Med* 2008; **178**: 261–68.
- 35 De Jonghe B, Sharshar T, Hopkinson N, Outin H. Paresis following mechanical ventilation. *Curr Opin Crit Care* 2004; 10: 47–52.
- 36 Griffiths RD, Palmer TE, Helliwell T, MacLennan P, MacMillan RR. Effect of passive stretching on the wasting of muscle in the critically ill. *Nutrition* 1995; **11**: 428–32.
- 37 De Jonghe B, Bastuji-Garin S, Fangio P, et al. Sedation algorithm in critically ill patients without acute brain injury. *Crit Care Med* 2005; 33: 120–27.

- 38 Schweickert WD, Gehlbach BK, Pohlman AS, Hall JB, Kress JP. Daily interruption of sedative infusions and complications of critical illness in mechanically ventilated patients. *Crit Care Med* 2004; 32: 1272–76.
- 39 Kortebein P, Ferrando A, Lombeida J, Wolfe R, Evans WJ. Effect of 10 days of bed rest on skeletal muscle in healthy older adults. JAMA 2007; 297: 1772–74.
- 40 Tesch PA, von Walden F, Gustafsson T, Linnehan RM, Trappe TA. Skeletal muscle proteolysis in response to short-term unloading in humans. J Appl Physiol 2008; 105: 902–06.
- 41 Sager MA, Franke T, Inouye SK, et al. Functional outcomes of acute medical illness and hospitalization in older persons. *Arch Intern Med* 1996; 156: 645–52.
- 42 Covinsky KE, Palmer RM, Fortinsky RH, et al. Loss of independence in activities of daily living in older adults hospitalized with medical illnesses: increased vulnerability with age. J Am Geriatr Soc 2003; 51: 451–58.
- 43 Mudge AM, Giebel AJ, Cutler AJ. Exercising body and mind: an integrated approach to functional independence in hospitalized older people. J Am Geriatr Soc 2008; 56: 630–35.
- 44 Inouye SK, Bogardus ST, Charpentier PA, et al. A multicomponent intervention to prevent delirium in hospitalized older patients. N Engl J Med 1999; 340: 669–76.
- 45 Marcantonio ER, Simon SE, Bergmann MA, Jones RN, Murphy KM, Morris JN. Delirium symptoms in post-acute care: prevalent, persistent, and associated with poor functional recovery. J Am Geriatr Soc 2003; 51: 4–9.
- 46 Jackson JC, Hart RP, Gordon SM, et al. Six-month neuropsychological outcome of medical intensive care unit patients. *Crit Care Med* 2003; 31: 1226–34.
- 47 Lin SM, Liu CY, Wang CH, et al. The impact of delirium on the survival of mechanically ventilated patients. *Crit Care Med* 2004; 32: 2254–59.
- 48 Hodgin KE, Nordon-Craft A, McFann KK, Mealer ML, Moss M. Physical therapy utilization in intensive care units: results from a national survey. *Crit Care Med* 2009; 37: 561–66.
- 49 Needham DM, Wang W, Desai SV, et al. Intensive care unit exposures for long-term outcomes research: development and description of exposures for 150 patients with acute lung injury. J Crit Care 2007; 22: 275–84.
- 50 Yohannes AM, Baldwin RC, Connolly MJ. Predictors of 1-year mortality in patients discharged from hospital following acute exacerbation of chronic obstructive pulmonary disease. *Age Ageing* 2005; 34: 491–96.
- 51 Walter LC, Brand RJ, Counsell SR, et al. Development and validation of a prognostic index for 1-year mortality in older adults after hospitalization. JAMA 2001; 285: 2987–94.
- 52 Poon WS, Zhu XL, Ng SC, Wong GK. Predicting one year clinical outcome in traumatic brain injury (TBI) at the beginning of rehabilitation. *Acta Neurochir Suppl* 2005; 93: 207–08.
- 53 Narain P, Rubenstein LZ, Wieland GD, et al. Predictors of immediate and 6-month outcomes in hospitalized elderly patients. The importance of functional status. J Am Geriatr Soc 1988; 36: 775–83.

economies that are working to address their own domestic tuberculosis problems. Worldwide, there are early signs of action. A group of countries, which together have nearly 45% of the world's tuberculosis and high rates of drug resistance, are leading new control efforts. In March, Brazil hosted the Stop TB Partners' Forum in Rio de Janeiro, and China convened a meeting of countries most affected by MDR tuberculosis. India has set an objective for universal access to MDR tuberculosis treatment and South Africa is home to crucial clinical research trials of vaccines, drugs, and diagnostics. These commitments could herald a new framework in global health in which endemic countries with emerging economies stimulate a global response.

*Martien W Borgdorff, Peter M Small

Academic Medical Centre, University of Amsterdam, 1100 DD Amsterdam, Netherlands (MWB); Bill & Melinda Gates Foundation, Seattle, WA, USA (PMS); and Institute for Systems Biology, Seattle, WA, USA (PMS) m.w.borqdorff@amc.uva.nl

We declare that we have no conflicts of interest.

- Wright A, Zignol M, Van Deun A, et al, for the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. *Lancet* 2009; published online April 16. DOI:10.1016/S0140-6736(09)60331-7.
- 2 WHO. Anti-tuberculosis drug resistance in the world: report 4. 2008 http:// www.who.int/tb/publications/2008/drs_report4_26feb08.pdf (accessed March 13, 2009).

- 3 Cobelens FG, Heldal E, Kimerling ME, et al. Scaling up programmatic management of drug-resistant tuberculosis: a prioritized research agenda. *PLoS Med* 2008; 5: e150.
- 4 Dye C. Doomsday postponed? Preventing and reversing epidemics of drug-resistant tuberculosis. *Nat Rev Microbiol* 2009; **7**: 81–87.
- 5 Zignol M, Hosseini MS, Wright A, et al. Global incidence of multidrug-resistant tuberculosis. J Infect Dis 2006; 194: 479–85
- 6 Cohen T, Colijn C, Wright A, Zignol M, Pym A, Murray M. Challenges in estimating the total burden of drug-resistant tuberculosis. *Am J Respir Crit Care Med* 2008; **177:** 1302–06.
- 7 Sandgren A, Strong M, Muthukrishnan P, Weiner BK, Church GM, Murray MB. Tuberculosis drug resistance mutation database. *PLoS Med* 2009; 6: e1000002.
- 8 Gagneux S, Davis Long C, Small PM, Van T, Schoolnik GK, Bohannan B. The competitive cost of antibiotic resistance in *Mycobacterium tuberculosis* resistance. *Science* 2006; **312**: 1944–46.
- 9 van Soolingen D, de Haas PE, van Doorn HR, Kuijper E, Rinder H, Borgdorff MW. Mutations at amino acid position 315 of the katG gene are associated with high-level resistance to isoniazid, other drug resistance, and successful transmission of Mycobacterium tuberculosis in the Netherlands. J Infect Dis 2000; 182: 1788–90.
- 10 Gagneux S, Burgos MV, DeRiemer K, et al. Impact of bacterial genetics on the transmission of isoniazid-resistant Mycobacterium tuberculosis. PLoS Pathog 2006; 2: e61.
- 11 WHO. WHO policy statement: molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis. 2008. http://www. who.int/tb/dots/laboratory/line_probe_assays/en/index.html (accessed March 13, 2009).
- 12 Raviglione MC, Uplekar MW. WHO's new Stop TB strategy. Lancet 2006; 367: 952–55.
- 13 DeRiemer K, García-García L, Bobadilla-del-Valle M, et al. Does DOTS work in populations with drug-resistant tuberculosis? *Lancet* 2005; 365: 1239–45.
- 14 Dye C, Williams BG, Espinal MA, Raviglione MC. Erasing the world's slow stain: strategies to beat multidrug-resistant tuberculosis. *Science* 2002; 295: 2042–46.
- 15 Mitnick C, Bayona J, Palacios E, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 2003; 348: 119–28.
- 16 Mitnick CD, Shin SS, Seung KJ, et al. Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med 2008; 359: 563–74.

🕡 Physical and occupational therapy during sedation stops

Published Online May 14, 2009 DOI:10.1016/50140-6736(09)60866-7 See Articles page 1874 Prolonged mechanical ventilation (eq, in acute respiratory distress syndrome) is associated with poor quality-adjusted survival in previously healthy patients.¹ During the past decade, the practice of weaning from mechanical ventilation and sedation, and the effect on outcome, has become a focus of research in intensive care. One problem with sedation is the insufficient attentiveness of treating teams towards the extent of sedation: in a large cohort study, oversedation was rated in less than 3% of cases, although patients were minimally arousable or non-arousable in more than 30% and motionless in more than 20% of the assessments.² Several trials³ have shown that sedation protocols that use target sedation and daily sedation stops can reduce time on mechanical ventilation and stay in intensive care. Moreover, protocols that pair daily spontaneous awakening trials with daily spontaneous breathing trials result in better outcomes for mechanically ventilated patients in intensive care than do current standard approaches.⁴

William Schweickert and co-workers went one step further.⁵ In *The Lancet* today, they report the effect of exercise and mobilisation during periods of daily sedation stops. They randomly assigned 104 sedated and mechanically ventilated patients to an intervention or a control group. The control group received standard therapy of daily sedation stops, which did not include mobilisation or exercise in most patients, and the intervention group received physical and occupational therapy. Intervention patients had greater independent function at hospital discharge than did the control group (primary endpoint, 59% vs 35%, p=0.02), reduced

Ahmed / Still Pictures

days of delirium while in intensive care (2 vs 4 days, p=0.02), and more days breathing without assistance (24 vs 21 ventilator-free days, p=0.05). Furthermore, intervention patients had higher Barthel scores (75 vs 55, p=0.05) at hospital discharge and ambulated greater distances without assistance (33 vs 0 m, p=0.004) than did those in the control group.

Exercise should have a central role in the treatment of critically ill patients. Even healthy adults lose skeletal muscle mass as a result of prolonged bed rest, particularly from the lower extremities. Adults aged 65 years and older have a greater loss of lean tissue in 10 days than do young people after 28 days.⁶ Although passive stretching can preserve the architecture of muscle fibres,⁷ even moderate resistance-exercise can counteract the decrease in synthesis of muscle protein seen with immobility.⁸ Furthermore, both paresis acquired in the intensive care unit and handgrip strength are independently associated with poor hospital outcomes.⁹ This finding suggests that preservation of muscle strength could improve outcomes.

Although physiotherapy is commonly administered to patients in intensive care during recovery from critical illness in the USA, the frequency and type of physiotherapy greatly varies between the type of hospital and clinical scenarios. Established hospital criteria for starting physiotherapy in the intensive care unit were present in only 10% of hospitals.¹⁰ Unfortunately, evidence is very scarce for the effectiveness of physiotherapy for critically ill adult patients, whether acute or chronic.¹¹

Early activity is feasible and safe in mechanically ventilated patients.¹² Patients with chronic obstructive pulmonary disease who need mechanical ventilation have a better exercise capacity after comprehensive early pulmonary rehabilitation, including deambulation, respiratory muscle training, and low-extremity training on a treadmill.¹³ In a prospective cohort study,¹⁴ early physical therapy reduced length of stay in intensive care and in hospital in survivors. This finding was not reproduced in the randomised study by Schweickert and co-workers (intensive care stay: intervention 5.9 days vs control 7.9 days, p=0.08; hospital length of stay: 13.5 days vs 12.9 days, p=0.93).

Although the effect of early exercise on days on mechanical ventilation, independent function, and ambulation is comprehensible, the effect on delirium deserves further attention. Assessment of delirium in

The printed journal includes an image merely for illustration

patients is difficult, even when sedation stops are used.¹⁵ The confusion assessment method for the intensive care unit might grossly over-diagnose delirium if sedation is restarted before the patient is awake (a Richmond agitation-sedation score of 0). Three positive criteria are needed for delirium, two of which are probably positive for most if not all sedated patients, including those undergoing a sedation stop but not reaching a Richmond score of 0. The criteria are: acute onset of mental status changes or a fluctuating course (positive for all sedated patients); inattention (positive for most with a Richmond score of 2 or less); and either disorganised thinking (probably positive if Richmond score is 2 or less) or altered consciousness (positive if Richmond score not 0). Whether actual delirium was reduced, or whether the physiotherapy and mobilisation merely enhanced reaching an awake state by provision of an incentive for not restarting sedation too early, is difficult to judge without information for Richmond score at the time delirium was diagnosed, and the individual components of the confusion assessment method. Because similar percentages of patients had sedation restarted for sustained anxiety or agitation, differences in delirium were probably related to patients remaining at low Richmond scores despite sedation stop. These points should be addressed in future studies.

*Stephan M Jakob, Jukka Takala

Department of Intensive Care Medicine, University and University Hospital, 3010 Bern, Switzerland (SMJ, JT) stephan.jakob@insel.ch

We declare that we have no conflicts of interest.

- Angus DC, Musthafa AA, Clermont G, et al. Quality-adjusted survival in the first year after the acute respiratory distress syndrome. *Am J Respir Crit Care Med* 2001; **163**: 1389–94.
- 2 Weinert CR, Calvin AD. Epidemiology of sedation and sedation adequacy for mechanically ventilated patients in a medical and surgical intensive care unit. *Crit Care Med* 2007; **35:** 393–401.
- 3 Kress JP, Pohlman AS, O'Connor MF, Hall JB. Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. N Engl J Med 2000; 342: 1471–77.
- 4 Girard TD, Kress JP, Fuchs BD, et al. Efficacy and safety of a paired sedation and ventilator weaning protocol for mechanically ventilated patients in intensive care (Awakening and Breathing Controlled trial): a randomised controlled trial. *Lancet* 2008; **371**: 126–34.
- 5 Schweickert WD, Pohlman MC, Pohlman AS, et al. Early physical and occupational therapy in mechanically ventilated, critically ill patients: a randomised controlled trial. *Lancet* 2009; published online May 14, 2009. DOI:10.1016/S0140-6736(09)60658-9.
- 6 Kortebein P, Ferrando A, Lombeida J, Wolfe R, Evans WJ. Effect of 10 days of bed rest on skeletal muscle in healthy older adults. JAMA 2007; 297: 1772–74.
- 7 Griffiths RD, Palmer TE, Helliwell T, MacLennan P, MacMillan RR. Effect of passive stretching on the wasting of muscle in the critically ill. Nutrition 1995; 11: 428–32.
- 8 Ferrando AA, Tipton KD, Bamman MM, Wolfe RR. Resistance exercise maintains skeletal muscle protein synthesis during bed rest. J Appl Physiol 1997; 82: 807–10.

- 9 Ali NA, O'Brien JM Jr, Hoffmann SP, et al, for the Midwest Critical Care Consortium. Acquired weakness, handgrip strength, and mortality in critically ill patients. *Am J Respir Crit Care Med* 2008; **178**: 261–68.
- 10 Hodgin KE, Nordon-Craft A, McFann KK, Mealer ML, Moss M. Physical therapy utilization in intensive care units: results from a national survey. *Crit Care Med* 2009; **37**: 561–66.
- 11 Gosselink R, Bott J, Johnson M, et al. Physiotherapy for adult patients with critical illness: recommendations of the European Respiratory Society and European Society of Intensive Care Medicine Task Force on Physiotherapy for Critically III Patients. *Intensive Care Med* 2008; 34: 1188–99.
- 12 Bailey P, Thomsen GE, Spuhler VJ, et al. Early activity is feasible and safe in respiratory failure patients. *Crit Care Med* 2007; **35:** 139–45.
- 13 Nava S. Rehabilitation of patients admitted to a respiratory intensive care unit. Arch Phys Med Rehabil 1998; **79:** 849–54.
- 14 Morris PE, Goad A, Thompson C, et al. Early intensive care unit mobility therapy in the treatment of acute respiratory failure. Crit Care Med 2008; 36: 2238–43.
- 15 Ruokonen E, Parviainen I, Jakob SM, et al, for the Dexmedetomidine for Continuous Sedation investigators. Dexmedetomidine versus propofol/ midazolam for long-term sedation during mechanical ventilation. Intensive Care Med 2009; 35: 282–90.

🕢 Child marriage in India: a tradition with alarming implications

Published Online March 10, 2009 DOI:10.1016/50140-6736(09)60452-9 See Articles page 1883 The earth is now inhabited by about 6.7 billion people. The population has grown nearly ten-fold in the past three centuries and has increased four-fold in the past century.¹ Between 2005 and 2050, eight countries, including India, are expected to contribute to half of the world's projected population increase.² China and India will most likely remain the only countries with populations over 1 billion, and probably no others

The printed journal includes an image merely for illustration

Activists carry children dressed as bride and groom to protest the practice of child marriage in India, at the World Social Forum in Mumbai, Jan 19, 2004 will come close to this level.³ India's population is a staggering 1.15 billion at present. This population explosion is detrimental not only for India but also for the entire world. It is important therefore to evaluate the various factors that have caused the increase, if one is to arrive at any long-term solutions.

The study by Anita Raj and colleagues, in *The Lancet* today, on the prevalence of child marriage in young women in India and its effect on fertility and fertility control, assesses one such important factor.⁴ Even today, 44.5% of marriages in India occur before the wife is aged 18 years, and are associated with high fertility and other disadvantages, such as multiple unwanted pregnancies. Marriage at such ages has enormous adverse implications, not just for women's health and empowerment in general, but also for humankind in the long term.

India is a large country with bewildering diversity. It is extremely difficult therefore to have a database that is both reliable and representative of the entire country. Raj and colleagues used data from the National Family Health Survey-3. This survey is the third large-scale multiround survey in a representative sample of households throughout India.⁵ All 29 Indian states were surveyed, with two specific goals: to provide essential data on health and family welfare needed by the Ministry of Health and Family Welfare and other